Flush with cash, BMS chief confirms '100% pharma' focus

Bristol-Myers Squibb ($BMY) CEO Lamberto Andreotti (photo) is happy he has $10 billion in cash to spend on small acquisitions that can bolster his pure-pharma strategy. He's especially happy most of it is already in the U.S., rather than subject to repatriation taxes. Report